India develops more potent Antibiotic that provides eight times higher efficacy than azithromycin

India has developed a new antibiotic, nafithromycin (Miqnaf), to combat drug-resistant pneumonia. Developed by Wockhardt with BIRAC support, this first-of-its-kind Indian antibiotic is more potent than existing options, requiring only a three-day course. Awaiting final approval, it promises higher effectiveness and fewer side effects, marking a significant advancement in the fight against antimicrobial resistance.